61 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
11 Mar 24
Report of Foreign Private Issuer
7:27am
expertise in clinical development, Can-Fite pursues a strategy of partnering with companies in specific geographic markets that specialize
424B3
CANF
Can-Fite Biopharma Ltd
22 Nov 23
Prospectus supplement
4:20pm
, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You are cautioned that any forward
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
24 Aug 23
Report of Foreign Private Issuer
7:19am
diseases of childhood, mucopolysaccharidosis type 6 and type 1. In addition, within the Telethon institutes a targeted therapeutic strategy is being
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
24 Apr 23
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
7:09am
, the Company’s Co-Founder and former Chairman, remains on the Board and will continue to guide the Company’s intellectual property strategy
6-K
EX-99.1
etjg3xk1
23 Nov 21
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
7:22am
6-K
EX-99.3
yyztj cnnv
26 Aug 21
Report of Foreign Private Issuer
7:28am
6-K
EX-99.1
udgo9b2i3098gi9 jb8h
30 Mar 21
In addition, to date ~$20 million in non-dilutive upfront payment received
8:09am
424B5
1x13ee69 co6rowi91x
8 Jul 20
Prospectus supplement for primary offering
10:42am
424B5
fwipl pekrb8
12 Jun 20
Prospectus supplement for primary offering
8:30am
424B4
m3o9og1 0byfj
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
we675 fmeh30z
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
ali3f8j5 epbkzz6l2q
24 Jan 20
Registration statement (foreign)
4:40pm
6-K
EX-99.1
nikrysmudhyni6a0z ev
6 Jan 20
Can-Fite CEO Issues Letter to Shareholders
7:17am
F-1/A
8qqh8n9r0rbb0y05
12 Jul 19
Registration statement (foreign) (amended)
4:38pm
F-1/A
cf4myzl66uxm
28 Jun 19
Registration statement (foreign) (amended)
4:32pm